Opinion

Video

The Evaluation of Dupilumab In Chronic Spontaneous Urticaria Treatment

Author(s):

Brian Keegan, MD, PhDGiselle Mosnaim, MD

A panel of experts discuss the clinical trials of dupilumab, the resultant data, and the response of the FDA when approval was requested.

Video content above is prompted by the following question:

  • Dupilumab has been evaluated in phase 3 clinical trials in patients with chronic spontaneous urticaria (CSU). What did the data show and what was the FDA’s response to the requested approval?
  • There is a Bruton tyrosine kinase (BTK) inhibitor under investigation in CSU. How does the BTK pathway differ from others that are targeted by CSU therapies?

a. BTK inhibitors are currently utilized in other disease states. What are the important clinical considerations with BTK inhibitors that clinicians should know?

b. How would the introduction of an oral therapy for CSU influence your treatment decisions?

Related Videos
A panel of 4 experts on chronic spontaneous urticaria
A panel of 4 experts on CLL
A panel of 4 experts on CLL
A panel of 4 experts on lung cancer
A panel of 4 experts on chronic spontaneous urticaria
Related Content
Silhouettes of different skin colors | Image Credit: freshidea - stock.adobe.com
September 17th 2024

Expert Highlights Need for Greater Diversity in Dermatology Clinical Trials

Brooke McCormick
Valerie M. Harvey, MD, MPH, FAAD, founder of the Hampton Roads Center for Dermatology, highlighted the long-standing underrepresentation of minority populations in dermatology clinical trials at the Skin of Color Update 2024 in New York City on Friday.
FDA approved stamp | Image Credit: Olivier Le Moal - stock.adobe.com
September 16th 2024

FDA Approves Lebrikizumab For Patients Aged 12 and Older With Moderate to Severe Atopic Dermatitis

Brooke McCormick
The FDA has approved lebrikizumab (Ebglyss; Eli Lilly) as a new first-line biologic treatment for patients aged 12 and older with moderate to severe atopic dermatitis (AD).
Image Credit: Andrew Popov - stock.adobe.com
September 13th 2024

Experts Highlight New Dermatological Treatments, Importance of Clinical Trial Diversity

Brooke McCormick
Experts at the Skin of Color Update today in New York City highlighted recent FDA-approved dermatological treatments and emphasized the importance of clinical trial diversity.
hands of a patient with vitiligo | Image Credit: Rabizo Anatolii - stock.adobe.com
September 5th 2024

Patients With Vitiligo Experience Poorer Quality of Life but Greater Health Care Access, Utilization

Brooke McCormick
Compared with those without vitiligo, patients with vitiligo have higher health care access and utilization but report a lower quality of life.
AJMC Q&A with Dr Kristen Whitney | Background image credit: ipopba - stock.adobe.com
August 28th 2024

Illuminating the Future: Dr Kristen Whitney on What's Next for Dermoscopy

Cameron Santoro Brooke McCormick
Kristen Whitney, DO, FAAD, dermatologist within the Allegheny Health Network, discusses advancements in dermoscopy, predicting that emerging technologies and artificial intelligence (AI) will improve dermatologists' efficiency in monitoring and diagnosing skin conditions.
Woman with vitiligo covering face with her hands | Image Credit: Savory - stock.adobe.com
August 19th 2024

Vitiligo, Mental Health Tied to Higher Health Care Utilization and Costs

Brooke McCormick
Patients with vitiligo and psychosocial comorbidities face significantly higher overall health care utilization and costs, although their vitiligo-related expenditures remain similar to those without such comorbidities.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2024 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
CH LogoCenter for Biosimilars Logo